Continuous and Non-invasive Detection of Heart Arrhythmias and Cuff-less & Absolute Blood Pressure Measurment by the Novel Cardiacsense Watch

• There is an unmet need for a continuous, long-term (28+ days), ambulatory, non-invasive medical device for monitoring of heart conditions and vitals
• CardiacSense has a clinically-proven technology to address these needs in a wristband form-factor
• So far clinical trials has shown over 99% sensitivity and specificity for A-Fib detection in ambulatory conditions.
• FDA and CE clearances for heart arrhythmias are expected by the end of 2019
• FDA and CE clearances for blood pressure monitoring are expected by 2020
• CardiacSense is targeting people that are over the age of 65 or poeple with high CHADS₂ Score for Atrial Fibrillation Stroke Risk
• We are also targeting people that are diagnosed with hypertention and are not contantly monitored

Commercial products will be available in 2020